Labgenomics announced on the 7th that it attended the ‘2024 Korean Dementia Association Special Symposium’ held on the 5th along with eight companies including Imocog.
The theme of the symposium was ‘Announcement of the Korean Dementia Association’s Recommendations for the Proper Use of Lecanemab and Sharing of Usage Experiences in Japan.’ Eight domestic healthcare specialized companies, including Korea Eisai, Imocog, and Labgenomics, which signed a multilateral Memorandum of Understanding (MOU) for innovation in dementia treatment paradigms, participated with an integrated booth.
Currently, the dementia management system remains a retrospective approach where treatment and care are provided after dementia symptoms have significantly progressed rather than early detection of cognitive decline. Through this integrated booth, the eight companies promoted an innovative platform that quickly and easily screens early-stage dementia such as Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) using Positron Emission Tomography (PET) scans and digital bio technologies, enabling patients to receive antibody treatment. They emphasized that this presents a new paradigm in dementia treatment and can greatly improve patients’ quality of life through more efficient and systematic early diagnosis and treatment.
Currently, one million people in Korea suffer from dementia, and the number is rapidly increasing due to accelerated aging. As of last year, the total annual management cost for dementia patients aged 60 and over reached 23.24 trillion KRW, with an average annual management cost per patient of approximately 23.24 million KRW, indicating a growing economic burden caused by dementia.
An official who attended the symposium said, “This conference provided a great opportunity to inform neurologists about the innovative dementia treatment paradigm being established by the eight companies,” adding, “Neurologists showed high interest, and we expect the pace of building a one-stop dementia treatment platform to accelerate in the future.”
The eight healthcare specialized companies plan to provide comprehensive dementia diagnosis and treatment solutions including ▲ amyloid antibody treatment (Korea Eisai) ▲ blood marker and genomic testing (Labgenomics, PeopleBio) ▲ PET imaging solutions (Brightonics Imaging) ▲ development and supply of PET radiopharmaceuticals for dementia diagnosis (Duchem Bio) ▲ brain disease imaging artificial intelligence (AI) solutions (Neurofit) ▲ health checkup linkage and follow-up health management (GC Care) ▲ online cognitive function testing and digital therapy (Imocog).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
